Transforming global cancer care and research
Accelerating cancer research and improving the quality of care requires collaboration across the entire cancer community. Flatiron Health UK works with NHS Hospitals, patients, charity organisations and researchers in both academia and industry to expand the impact of real-world evidence in cancer.
Through clinical data and data science, and adherence to strict data privacy requirements, we translate actual patient experiences into real-world evidence to improve patient outcomes, inform policy and advance research.
Our mission
To improve and extend lives by learning from the experience of every person with cancer.
About Flatiron Health UK
Flatiron Health UK brings together the best minds in medicine and technology to transform how cancer is researched and treated. Today, the experiences of only a small percentage of cancer patients are represented in the clinical trials that currently form the evidence base for most treatment, drug development and regulatory decisions.
Flatiron Health UK helps to fill this gap by transforming information from electronic health records into high-quality real-world evidence (RWE) that helps address new and previously hard to answer questions.
Flatiron Health was founded in 2012
Since then, Flatiron data in the United States have:
supported meaningful insights relevant to a global cancer population
been featured in hundreds of peer-reviewed publications
informed decisions by regulators and health technology appraisal (HTA) bodies around the world
illuminated the impact of U.S. healthcare policy on racial disparities in time to treatment
supported post-approval regulatory decision-making in ways that directly impact patient care, such as reducing the frequency of treatment visits from weekly to fortnightly
Our vision
To improve cancer outcomes and care using cancer data.
Our approach
Data for cancer care and research
We work with hospitals to translate cancer patients’ real-world experiences into research-ready datasets. We support NHS clinicians, researchers and data managers to use this data to improve patient care and outcomes, in ways that fit into routine clinical care and workflows.
Benefits for patients
Flatiron Health UK’s real-world cancer datasets help researchers, HTA bodies and regulators optimise and improve cancer therapies—and help get them to patients more quickly. The value we generate from our industry partnerships is shared through a fair value exchange with our NHS Hospital partners to support research, planning and improve patient care. To do this effectively, we work closely with our Patient Voices Panel.
Benefits for patients
Flatiron Health UK’s real-world cancer datasets help researchers, HTA bodies and regulators optimise and improve cancer therapies—and help get them to patients more quickly. The value we generate from our industry partnerships is shared through a fair value exchange with our NHS Hospital partners to support research, planning and improve patient care. To do this effectively, we work closely with our Patient Voices Panel.
Advancing application of RWE in the UK
Flatiron Health UK is also privileged to partner with the National Institute for Health and Care Excellence (NICE) and work with Health Data Research UK (HDR UK), DATA-CAN, the HDR UK Hub for Cancer and other national organisations to advance the understanding and application of RWE, which supports the NHS and benefits UK cancer patients.
Our commitment
To patients
Patients and patient advocacy groups are central to informing and shaping our work. Learn more about Flatiron Health UK's Patient Voices Panel in this blog: A co-created cancer data knowledge network to deliver better outcomes and higher societal value.
To privacy and security
Generating high-quality cancer real-world evidence requires working with patients’ medical information securely. Flatiron Health UK respects patients’ privacy and protects their medical information at all times, is Cyber Essentials Plus certified and completes the annual NHS Data Security & Protection Toolkit. A Data Protection Officer monitors compliance at dpo.flatiron@kdpc.uk.
Working with the NHS to create value across the UK cancer community
The NHS Hospital applies opt-outs, including the National data opt-out, to respect the wishes of patients who do not want to share their confidential information for research and planning purposes.
Flatiron Health UK securely accesses cancer data and sends back organised, easy-to-use information to the NHS Hospital. Data is anonymised before it leaves the hospital. For more, see Patient Data Privacy Notice.
Researchers will access and study the anonymised data to improve patient outcomes in a secure Trusted Research Environment.
Research will be reviewed by an oversight group that includes clinicians and patients.
Industry research partners pay Flatiron Health UK a licence fee to access anonymised real-world datasets. They can use this data to better understand and improve cancer therapies—and try to get these to patients faster.
Flatiron Health UK complies with GDPR, UK data protection law and NHS security policies.
Flatiron Health UK shares value generated from the anonymised real-world datasets with NHS Hospitals. NHS Hospitals can use this to improve capacity, cancer research and the care that patients receive.
News
Want to learn more about applications of real-world data?
Our leadership team
Dr. Blythe Adamson
Head of Outcomes Research and Evidence Generation, International
Michael Bierl
GM, Europe
Lauren Brown
Head of Product International & General Manager Japan
Finn Dierks
Senior Director, Legal
Adam Manhi
Head, Market Development and Partnerships
Matt Murchison
Head of Engineering, International
Amit Samani, PhD
Medical Director
Dr. Kathi Seidl-Rathkopf
Data Insights Lead, International
Arun Sujenthiran, FRCS, MD(Res)
Clinical Lead and Senior Medical Director, Caldicott Guardian
Join our team
Patient Voices Panel
Our Patient Voices Panel helps us to reflect and respond to the voices and experiences of UK cancer patients and carers in our work. See what we've been up to in our Impact Report.
Helen Bulbeck
Helen is co-founder of brainstrust, having experienced cancer as both a patient and a caregiver. She is passionate about using her experience to support the thousands of patients who have brain cancer and brings a PPI perspective to all cancers.
Chris Carrigan
Chris is a founding member of useMYdata, COO of DATA-CAN and serves as an expert advisor to Flatiron Health UK's Patient Voices Panel. Chris has worked across the UK patient data landscape for more than 20 years.
Linda Galbraith
Linda, a collector of rare diseases, joined the Flatiron Health UK Patient Voices Panel last year, with a background in health service management, psychology and board membership, primarily in the third sector.
Bob White
Bob was diagnosed in 2011 with prostate cancer and is now in remission. Bob runs a local prostate cancer support group (Prostaid) and is passionate about the treatment and outcomes of men with prostate cancer. Bob believes the use of patient data is a vital ingredient in the national fight against all types of cancer. Prior to his retirement, Bob was a senior police officer and then a senior fraud investigator in the banking and insurance industries.
Terry Lock
Terry is a retired IT professional. He is actively involved in a number of different health groups advising on the use of and access to patients data, both locally in Nottinghamshire and across the UK. Terry enjoys the chance to leverage his skills and expertise to help benefit patients and the public. He has no lived experience of cancer and is a lay representative on the Patient Voice Panel.
Emily Bridges
Emily is an experienced content creator and communications expert. She is the co-founder of IBDrelief, a for-purpose start-up focused on improving disease education for inflammatory bowel disease patients and has recently taken on the role of Head of Content & Engagement at a charity. She has no lived experience of cancer and is a lay representative on the Patient Voice Panel.
Former panel members
Della (Dolapo) Ogunleye
As a founding member of the Patient Voices Panel, Della brought her unique energy, enthusiasm and insight. We are grateful to have been part of her outstanding commitment to patient advocacy, and diversity in research, during the final years of her own cancer journey.
Lesley Shannon
Lesley helped found the Patient Voices Panel, and contributed her insights and guidance during its first years. She brought to the panel her unique perspective on colorectal cancer and research. She shared her experience and learning from her on-going work advocating in Scotland and beyond for improvements to the cancer journey, including early diagnosis. While no longer a panel member Lesley continues to advocate for cancer research and improvements in patient care.
Interested in learning more?
We will email you to start the conversation.